secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001453687-24-000052
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics enters employment pacts with CSO Jewell ($420K) and CTO Kurtoglu ($440K)
--------------------------------------------------------------------------------

- Christopher Jewell appointed CSO; annual base salary $420,000, target bonus 40%.
- Metin Kurtoglu appointed CTO (was COO); annual base salary $440,000, target bonus 40%.
- Severance: 12 months base pay, prorated bonus, and COBRA if terminated without cause or for good reason.
- Change-in-control provision: accelerated vesting of time-based equity awards if termination occurs near a change.
- Both executives subject to 12-18 month non-compete, non-solicit, and confidentiality covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/0001453687-24-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/rnac-20240326.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer